Anti-Inflammatory Peptides Market
Number of pages: 100 | Report Format: PDF | Published date: February 06, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market Size Value in 2021 |
US$ 98 billion |
|
Revenue Forecast in 2030 |
US$ 139.4 billion |
|
CAGR |
4% |
|
Base Year for Estimation |
2021 |
|
Forecast Period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments Covered |
Application, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global anti-inflammatory peptides market is valued at US$ 98 billion in 2021 and is expected to register a revenue CAGR of 4% to reach US$ 139.4 billion by 2030.
Anti-Inflammatory Peptides Market Fundamentals
Anti-inflammatory peptides (AMPs) are small yet effective compounds that inhibit or delay the swelling of the skin and mucous membranes and harm the air passages in the lungs. AMPs are effective, broad-spectrum antibiotics with promise as cutting-edge medicinal medicines. It has been shown that antimicrobial peptides may eradicate gram-positive and gram-negative bacteria, envelop viruses, fungi, and even altered or malignant cells.
The exorbitant expense of generating naturally derived AMPs has encouraged research in recent years to create synthetically manufactured mimics of antimicrobial peptides, such as SNAPPs. The C-terminal domain of human platelet factor IV was used to create the facially cationic peptide C18G, which illustrates this. Nisin, the only antimicrobial peptide that has received FDA approval, is the antimicrobial peptide that is most frequently used as a synthetic preservative. In contrast to the majority of traditional antibiotics, AMPs appear to regularly disrupt biological membranes, generate transmembrane channels, and even boost immunity by acting as immunomodulators.
Non-specific anti-Inflammatory medications and another immunosuppressant are currently used as a treatment for inflammatory and autoimmune disorders. However, these medications frequently come with the risk of side effects. AMPs are currently used as an alternative medicine to treat various inflammatory disorders, including Alzheimer's disease and rheumatoid arthritis. It is crucial to understand the relationship between an amino acid sequence and its possible anti-inflammatory function in order to find new and effective anti-inflammatory peptide therapies. Understanding the relationship between amino acid sequence and possible Anti-Inflammatory properties is crucial to develop new and effective anti-inflammatory peptide-based therapies. AMPs have been employed as medicinal agents. However, due to their short half-lives, their usage is mostly restricted to intravenous injection or topical treatments.
[85674564]
Anti-Inflammatory Peptides Market Dynamics
The global anti-inflammatory peptides market is anticipated to expand at a significant revenue CAGR over the next years due to rise in the prevalence of autoimmune illnesses, inflammatory bowel disease, multiple sclerosis, and psoriasis cases. According to a 2013 World Psoriasis Day estimate, 3% to 4% of the world's population, or over 130 million people, are affected by this condition. The growing elderly population base around the world is another significant factor driving the expansion of this market. The need for AMPs increases due to aging, which shifts the body's natural immunity in favor of a pro-inflammatory state.
Unhealthy lifestyles and rising levels of patient knowledge about the need for prompt treatment of different ailments are further driving the global market for anti-inflammatory peptides. The expansion of the global market for anti-inflammatory peptides is anticipated to be aided by the alarming increase in the prevalence of autoimmune and respiratory disorders, new therapies in development, and rising consumer acceptance of Anti-Inflammatory pharmaceuticals. Demand for Anti-Inflammatory pharmaceutical pharmaceuticals has increased dramatically due to the development of Anti-Inflammatory biologics that are more effective, targeted, and have fewer side effects than conventional medications. During the projection period, there are expected to be abundant prospects for market expansion due to ongoing research to discover new and efficient anti-inflammatory peptides.
Anti-Inflammatory drug usage may have side effects, which have grown more significant over time. Fluid retention reduces renal blood flow, and gastrointestinal bleeding is a side effect of these drugs. Additionally, ingesting them results in stomach ulcers, known as peptic ulcers. Many pills or injections are now going through the drug approval process. Obtaining regulatory approval for the drug is time-consuming and challenging since regulatory organizations, such as the U.S. FDA, have stringent requirements for companies that work in clinical research, marketing, manufacturing, and distribution of medicines.
Anti-Inflammatory Peptides Market Ecosystem
The global anti-inflammatory peptides market has been analyzed from three perspectives: application, distribution channel, and region.
Anti-Inflammatory Peptides Market by Application
[35475744]
Based on the application, the global anti-inflammatory peptides market has been segmented into gastrointestinal diseases, neurological diseases, cardiovascular diseases, dermatological diseases, renal diseases, ophthalmological diseases, transplantation, respiratory diseases & pulmonary disorders, and rheumatological & autoimmune diseases.
Due to the increasing prevalence of cardiovascular issues among the global population, the cardiovascular diseases segment accounts for the largest revenue share of the global anti-inflammatory peptides market. Additionally, factors such as the increasing aging population and rising rates of obesity caused due to unhealthy lifestyles contribute to the domination of this segment.
Other anti-inflammatory medications have recently demonstrated the capacity to lower the incidence of cardiovascular events in secondary prevention, such as canakinumab and colchicine.
Anti-Inflammatory Peptides Market by Distribution Channel
Based on the distribution channel, the global anti-inflammatory peptides market has been segmented into hospital pharmacy, retail pharmacy, and online pharmacy.
The hospital pharmacy segment dominates the global anti-inflammatory peptides market due to the increased prevalence of inflammatory diseases, expanding need for anti-inflammatory drugs, and favorable health reimbursement policies. The demand for ibuprofen, diclofenac, and OTC medications is predicted to increase, leading to revenue growth in the retail pharmacy segment. Additionally, the online segment is anticipated to grow at a significant revenue CAGR due to rising e-commerce usage, enhanced patient convenience, and attractive discounts and coupons on online purchases.
Anti-Inflammatory Peptides Market by Region
Based on the region, the global anti-inflammatory peptides market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World.
Due to extensive research and development efforts, the availability of technologically advanced systems, and rising patient awareness, North America is projected to dominate the global market for anti-inflammatory peptides. The high frequency of psoriasis and multiple sclerosis is crucial in North America’s leadership position.
Due to an increase in both private and public associations, which has led to an increase in financing and, consequently, growth in demand for anti-inflammatory peptides, Latin America is also expected to expand at a healthy revenue CAGR during the forecast period.
The rapid advancement in the healthcare infrastructure in Asia Pacific is expected to result in significant revenue growth in the regional market during the forecast period. Rising patient awareness and increase in the number of patients in the regional countries are influencing the progress of the Asia Pacific market.
Anti-Inflammatory Peptides Market Competitive Landscape
The prominent players operating in the global anti-inflammatory peptides market are:
Anti-Inflammatory Peptides Market Strategic Developments
The global anti-inflammatory peptides market is expected to register a revenue CAGR of 4% during the forecast period from 2022 to 2030.
Araim Pharmaceuticals, Inc., Novartis AG, AbbVie Corporation, Pfizer Inc., and Eli Lilly and Company are among the key players operating in the global anti-inflammatory peptides market.
The cardiovascular diseases segment dominates the global anti-inflammatory peptides market.
Asia Pacific is expected to register the highest revenue CAGR in the global anti-inflammatory peptides market during the forecast period from 2022 to 2030.
The global anti-inflammatory peptides market was valued at US$ 98 billion in 2021.
*Insights on financial performance are subject to the availability of information in the public domain